Schedule

Coming Soon…

The presentation will provide an update on the use of ketamine for treatment resistant depression. We will briefly review the history of ketamine as an antidepressant, the evidence supporting its use for depression, as well as consideration of potential risks and benefits, and the logistics of initiating ketamine treatment, including the potential use of varying formulations (i.e. IV, intranasal, PO).

Learning Objectives

1. Describe the existing evidence supporting the use of ketamine for depression.

2. Describe how and when to use ketamine for depressed patients.

This presentation will review traditional non-medication interventions such as behavioral therapy and cognitive therapy for ADHD in children. The talk will also present novel interventions including neuromodulation and dietary approaches to treat ADHD.

Learning Objectives

1. Improve understanding of when to recommend traditional non-medication treatments (such as behavior therapy & cognitive behavioral therapy) and for ADHD in children.

2.Improve understanding of scientific updates on novel non-pharmacological interventions (such as neuromodulation, neurofeedback, and dietary approaches) for ADHD treatment.

3. Discuss integrated treatment approaches for children and adolescents with ADHD.

Suicides and self-harm are leading causes of morbidity and mortality in youth. This presentation will improve participant understanding of the risk factors for self-harm in youth and evidence based interventions to reduce harm in this population.

Learning Objectives

1. Name two steps in the process of care for youth presenting with suicidal ideation or behavior.

2.Describe one intervention for youth presenting with elevated suicide risk that has evidence supporting efficacy for reducing the risk of self-harm including suicide attempts.

3.Describe one risk factor and one protective factor for suicide attempts in youth.

This presentation will provide an update on the treatments for Borderline Personality Disorder with a specific focus on evidence-based psychotherapies.  The role of pharmacological interventions will also be discussed.

Learning Objectives

1.Identify diagnostic factors that indicate the need for, direct therapy toward, therapy specific for Borderline Personality Disorder.

2.Recognize the difference in the evidence-based treatments for BPD which can inform when directing toward treatment.

3.Recognize the limited role of medications and better assess the need for them when evaluating patients with BPD.

This presentation will describe what we know and what we don’t know about the genetic basis of psychiatric disease. The implication of findings for clinical practice, that is diagnose and treatment, will be discussed.

Learning Objectives

1. Know the heritabities of common psychiatric illness (schizophrenia, bipolar disorder, depression, anxiety disorders).

2. Describe the genetic architecture of common psychiatric illness.

3. Describe how diagnostic categories relate to molecular genetic categories of common psychiatric illness.

This talk will examine the history and current status of the psychedelic treatment model in psychiatry. We will discuss the rationale, therapeutic structures and safety parameters for psychedelic assisted psychotherapies.

Learning Objectives

1. Examine the range of plant-based and laboratory synthesized psychedelics that have potential use in psychiatric treatment.

2. Understand the necessity of optimizing treatment structures to ensure therapeutic and safe outcomes.

3. Be aware of current trends and challenges in the field of psychedelic medicine and how they may impact treatment delivery in the future.

This presentation will introduce the concept and definition of the Collaborative Care Model and help clinicians better fulfill their role in this care model.

Learning Objectives

1. Describe the evidence base for Collaborative Care.

2. Define the Collaborative Care Model.

3. Identify measurement-based care practices within Collaborative Care.

The presentation will provide definitions of LGBTQ identities, define minority stress theory, and describe its impact on LGBTQ mental health. This presentation will also highlight issues of equity, diversity, and inclusion (EDI) and its importance in meeting the needs of racial minority LGTBQ youth.

Learning Objectives

1. Describe theory of minority stress and apply to LGBTQ mental health risk.

2. Identify at least two risk factors for psychiatric illness and suicide in LGBTQ youth and young adults.

3. Identify at least one protector factor or community resource for LGBTQ youth.

Adolescence is a period marked by significant behavioral and emotional changes which can obscure the onset of a psychosis prodrome. This presentation will review how to differentiate the psychosis prodrome from normal adolescent behavior and how to manage the prodrome.

Learning Objectives

1. Describe how to differentiate depression from the psychosis prodrome.

2. Understand the importance of recognizing psychosis and minimizing the duration of untreated psychosis,

Declines in memory and cognitive functioning can be a part of normal aging. This presentation will review the evidence for memory and cognitive training to slow this decline in older adults.

Learning Objectives

1. Describe memory changes in normal vs abnormal (dementia) aging.

2. Describe three approaches to cognitive training.

3. Describe three effects on cognitive training on brain plasticity.

Physicians are at high risk for substance use disorders due to the high stress nature of their job and access to controlled substances. This presentation will review risk factors and treatment options for this unique population.

Learning Objectives

1. Understanding the environmental and workplace risks impacting Substance Use in medical professionals.

2. Identifying resources and support available to medical professionals seeking recovery from substance use.

This presentation will discuss the intersection and interaction of anxiety disorders and substance use disorders. Clinicians will learn about pharmacological and cognitive behavioral approaches to treatment.

Learning Objectives

1. Understand the scope of the problem of comorbid anxiety and substance use disorders and how this comorbidity develops.

2. Describe the main components of treatment for co-occurring anxiety and substance use disorders.

3. Describe ways in which traditional cognitive behavioral treatment for anxiety disorders should be adapted to meet the needs of a SUD population.

Alcohol use disorder remains one of the most prevalent and impairing substance use disorders despite numerous pharmacotherapy treatment options. This presentation will review the effects of alcohol misuse and the available pharmacotherapies to treat alcohol misuse.

Learning Objectives

1. Describe the psychiatric and medical complications from alcohol use disorder.

2. Describe the mechanism of long acting injectable medications which can be used to treat alcohol use disorder.

This presentation will provide an overview of repetitive transcranial magnetic stimulation (rTMS) interventions in the treatment of major depressive disorder (MDD). We will discuss risks and benefits associated with this non-invasive brain stimulation intervention.

Learning Objectives

1. Describe two FDA cleared rTMS strategies for major depressive disorder.

2. List common and severe side effects associated with rTMS.

3. Describe response and remission rates associated with rTMS treatment in MDD.

The importance of providing culturally competent care is highlighted by improved health outcomes when these factors are recognized by providers. This presentation will review how clinicians can deliver improve their ability to deliver care informed by cultural considerations.

Learning Objectives

1. Describe how physicians and other medical professionals are at risk for developing substance use disorder.

2. Describe how stigma and lack of awareness of SUD and treatment options lead to delays in care and poor outcomes, and can lead to loss of a license to practice.

3. Describe the importance of seeking professional treatment for SUD early in the illness

This presentation will address the connection between estrogen fluctuation across the lifespan and its impact on women’s health, including depression and cognitive functioning. Research on hormone replacement therapy (HRT) for the post-menopausal woman, including the risks and benefits for both mood and memory, will be discussed.

Learning Objectives

1. Understand the role of estrogen in the developing and aging brain.

2. Describe the connection of estrogen and depression for PMS and PMDD.

3. Understand how HRT impacts mood and memory after menopause.

Coming Soon…